Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Leukemia
Safety and Efficacy of Decitabine + Ipilimumab in Relapsed/Refractory MDS/AML in Posttransplant or Transplant-Naïve Settings
Read More
The First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine Is Well-Tolerated and Effective in Patients with AML
Read More
Venetoclax Added to Cladribine plus Low-Dose Ara-C Alternating with 5-Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Read More
MBG453 in Combination with Hypomethylating Agents in Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Read More
Phase 2 Study of CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia
Read More
Decitabine + Venetoclax Compared with Intensive Chemotherapy in AML: A Propensity Score–Matched Analysis
Read More
Retrospective Study of Single Cord Blood Transplantation for Patients with AML Aged ≥60 Years
Read More
Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML
Read More
The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia
Read More
Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis
Read More
1
2
3
4
5
6
7
Page 4 of 7
Results 31 - 40 of 64